Depo-Provera and Meningioma: What the Evidence Shows in 2026

Start with the condition, not the lawsuit

A meningioma is a tumor arising from the membranes surrounding the brain and spinal cord. Many are histologically benign, but location, size, growth and pressure on nearby structures can make them medically serious. Symptoms and treatment vary, and a diagnosis requires clinical evaluation and imaging rather than a symptom list on a legal website. Hormonal biology has long been relevant to meningioma research, including the presence of progesterone receptors in many tumors, but biological plausibility is not the same as proof that one medicine caused one tumor.

Depo-Provera CI contains medroxyprogesterone acetate and is administered as a depot injection. The litigation focuses heavily on repeated or prolonged exposure and alleged intracranial meningioma. The useful scientific question is not whether nausea, headache or a single injection automatically means tumor risk. It is whether exposed populations show a different rate or odds of meningioma than suitable comparison populations, and whether study design, duration, dose, confounding and diagnostic capture support the interpretation.

The 2024 French study that changed the conversation

Roland and colleagues used France's national health data in a case-control study published in BMJ. The analysis included 18,061 women who underwent intracranial meningioma surgery from 2009 through 2018 and 90,305 matched controls. For prolonged injectable medroxyprogesterone acetate use, the paper reported an odds ratio of 5.55 with a 95% confidence interval of 2.27 to 13.56. “Prolonged” meant use for a year or longer in the study's exposure framework.

That figure deserves both attention and context. It is a relative odds measure, not a statement that one in five users develops a tumor. Only a small number of study participants had the relevant MPA exposure, producing a wide confidence interval. The design was observational and based on health records and reimbursement data, not randomized assignment. It examined surgically treated intracranial meningioma in France, so it cannot by itself answer every question about U.S. use patterns, tumor detection or an individual's competing risk factors.

What later U.S. data added

A 2024 U.S. commercial-insurance case-control study reported that injection MPA exposure was associated with 53% higher odds of being a meningioma case, with a stronger association for longer use. A later population-based cohort study using the TriNetX network reported a relative risk of 2.43 for a subsequent meningioma diagnosis among DMPA users compared with controls after matching. It reported that the signal was concentrated among people with more than four years of exposure or who began after age 31.

The TriNetX authors also calculated a high number needed to harm and described overall clinical risk as low. That is not contradictory: a rare outcome can have an elevated relative risk while remaining uncommon in absolute terms. Database studies also share limitations. Coding may imperfectly represent exposure and diagnosis; residual confounding can remain after matching; adherence and cumulative dose can be difficult to reconstruct; and increased medical contact can affect detection. Consistency across datasets strengthens a signal without making every bias disappear.

The FDA label now carries a specific warning

FDA approved a supplemental labeling change in 2025 for Depo-Provera CI and depo-subQ provera 104. The approval letter says the supplement added meningioma-risk information to Warnings and Precautions, Patient Counseling Information and patient materials. The current label states that meningioma cases have been reported after repeated administration of medroxyprogesterone acetate, primarily with long-term use; it directs monitoring for signs and symptoms and discontinuation if a meningioma is diagnosed.

Compare that with the 2024 FDA label, whose major warnings centered on issues such as bone mineral density and did not include the later dedicated meningioma section. The before-and-after record establishes a regulatory history. It does not establish that the pre-2025 label violated a particular state's law, that FDA found negligence, or that all users face the same risk. Those are different legal and individual medical questions.

What can—and cannot—be concluded for one person

The evidence supports taking the association seriously, particularly in research on repeated, longer-duration injected MPA exposure. It also supports careful communication about absolute risk and uncertainty. The studies do not create a diagnostic test. A person with concerning neurologic symptoms needs a clinician, and a person with an existing meningioma needs individualized advice about medication and tumor management. No one should stop a prescribed contraceptive solely because of a lawsuit page without discussing alternatives and risks with a licensed professional.

In court, general causation and specific causation are separate. Even if experts are permitted to testify that DMPA can cause meningioma under some conditions, an individual case may still require reliable proof of the actual product, exposure duration, diagnosis, timing and alternative explanations. MDL 3140 had a Rule 702 hearing scheduled for July 27, 2026 as of this update. The scientific literature informs that dispute; the court determines admissibility, and a factfinder or agreement process addresses individual outcomes.

Reader questions

Frequently asked questions